SACK1A and neoplasm: It has been demonstrated in a model of breast cancer that FAM83A acts downstream of the EGFR signaling and exerts oncogenic properties by promoting tumor growth, and conferring resistance to EGFR-tyrosine kinase inhibitors [58].